Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia

Biologics: Targets and Therapy

Volumn 3, Issue , 2009, Pages 205-214

  Ramchandren, Radhakrishnan ^a   Schiffer, Charles A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic myeloid leukemia (CML); Dasatinib; Imatinib; Nilotinib; Resistance (imatinib resistance); Tyrosine kinase inhibitor

Indexed keywords

EID: 77957067159     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S3791     Document Type: Review

References (55)

1. Talpaz M, Shah NP, et al. 2006. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 354(24):2531-2541.
2. Hochhaus A, Baccarani M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22(6):1200-1206.
3. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 2007;357(3):258-265.
4. Druker BJ, Guilhot F, et al. 2006. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 355(23):2408-2417.
5. Olivieri, A, Manzione L. Dasatinib: a new step in molecular target therapy. Ann Oncol. 2007;18 Suppl 6:vi42-46.
6. Quintas-Cardama A, Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res. 2008;14(14):4392-4399.
7. Quintas-Cardama A, Cortes J. Management of patients with resistant or refractory chronic myelogenous leukemia. Oncology (Williston Park). 2008;22(4):430-7; discussion 437, 442, 446 passim.
8. Thomas DA, Faderl S. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood, 2004;103(12):4396-4407.
9. Donato NJ, Wu JY, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101(2):690-698.
10. Porkka, K, Koskenvesa, P, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008;112(4): 1005-12.
11. Amrein PC, Attar EC, et al. A phase II study of dasatinib in relapsed and refractory chronic lymphocytic leukemia (CLL/SLL). Blood. (ASH Annual Meeting Abstracts). 2007;110:3126.
12. Chiappori AA, Tanvetyanon T, et al. Phase I trial evaluating the epidermal growth factor receptor inhibitor erlotinib in combination with the SRC kinase inhibitor dasatinib for patients with recurrent nonsmall cell lung cancer (NSCLC). J Clin Oncol. 2008;26(May 20 suppl): abstr 14605.
13. Esteve FR, Stoller RG, et al. 2008. Phase I trial of cetuximab (C) and dasatinib (D) in patients (pts) with advanced solid malignancies. J Clin Oncol. 2008;26(May 20 suppl):abstr 14668.
14. Kopetz S, Wolff RA, et al. Phase I study of Src inhibition with dasatinib in combination with 5-fluoruracil, leucovorin, oxaliplatin (FOLFOX) and cetuximab in metastatic colorectal cancer. ASCO Gastrointestinal Symposium. 2008;Abstract No: 325.
15. Yu EY, Wilding G, et al. Dasatinib in patients with hormonerefractory progressive prostate cancer: A phase II study. J Clin Oncol. 2008;26(May 20 suppl):abstr 5156.
16. Aguillon RA, Llanos CA, et al. Dasatinib induces apoptosis in chronic lymphocytic leukemia and enhances the activity of rituximab and fludarabine. Blood. (ASH Annual Meeting Abstracts). 2007;110:1116.
17. Baumgartner C, Gleixner KV, et al. Dasatinib inhibits the growth of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFR. Blood. (ASH Annual Meeting Abstracts). 2007;110:3559.
18. Rondoni M, Paolini S, et al. Response to dasatinib in patients with aggressive systemic mastocytosis with D816V kit mutation. Blood. (ASH Annual Meeting Abstracts). 2007;110:3562.
19. Wildes TM, Ruddell A, et al. The activity and toxicity of dasatinib in relapsed or plateau-phase multiple myeloma. Blood. (ASH Annual Meeting Abstracts). 2007;110:1182.
20. Dasatinib (sprycell) for CML and Ph22ALL. Med Lett Drugs Ther 2007;49:1252.
21. Copland M, Hamilton A, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107(11):4532-4539.
22. Kantarjian H. CML From Bench to ODAC Educational Session; 2006.
23. Hochhaus A, Kantarjian HM, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6): 2303-2309.
24. Mauro MJ, Baccarani M, et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol. 2008;26(May 20 suppl):abstr 7009.
25. Kantarjian H, Schiffer C, et al. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood. 2008;111(4):1774-1780.
26. Guilhot F, Apperley J, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109(10):4143-4150.
27. Guilhot F, Apperley J, et al. Efficacy of dasatinib in patients with accelerated phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2 year follow-up data from START-A (CA180-005). Blood (ASH Annual Meeting Abstracts Nov 2007). 2008;110:470.
28. Cortes J, Rousselot P, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109(8):3207-3213.
29. Gambacorti C, Cortes J, et al. Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START Program. Blood. (ASH Annual Meeting Abstracts). 2007;110:472.
30. Ottmann O, Dombret H, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007;110(7):2309-2315.
31. Foa R, Vignetti M, et al. Dasatinib as front-line monotherapy for the induction treatment of adult and elderly Phiiacute lymphoblastic leukemia (ALL) patients: interim analysis of the GIMEMA Prospective Study LAL1205. Blood. (ASH Annual Meeting Abstracts). 2007;110:7.
32. Ravandi F, Thomas D, et al. Phase II study of combination of the hyperCVAD regimen with dasatinib in patients with Philadelphia chromosome (Ph) or BCR-ABL positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB). Blood. (ASH Annual Meeting Abstracts). 2007;110:2814.
33. Stone RM, Kantarjian HM, et al. Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013). Blood (ASH Annual Meeting Abstracts). 2007;110:734.
34. Quintas-Cardama A, Kantarjian H, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25(25):3908-3914.
35. Punnialingam S, de Lavallade H, et al. Pleural effusions associated with use of dasatinib in chronic myeloid leukemia may have an autoimmune pathogenesis. Blood. (ASH Annual Meeting Abstracts). 2007;110:2945.
36. Mustjoki S, Laurinolli T, et al. Clonal large granular lymphocyte (LGL) expansion associated with dasatinib therapy. Blood. (ASH Annual Meeting Abstracts). 2007;110:2938.
37. Zamoyska R, Basson A, et al. The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation. Immunol Rev. 2003;191:107-118.
38. Shah NP, Kantarjian HM, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26(19):3204-3212.
39. www.clinicaltrials.gov. Advanced chronic myelogenous leukemia (CML)-follow on: study of BMS-354825 in subjects with CML. ClinicalTrials.gov Identifier: NCT00123487.
40. Kantarjian H, Pasquini R, et al. Dasatinib or high-dose imatinib for chronicphase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109(12):5143-5150.
41. Kantarjian H, O'Brien S, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer. 2007;109(8):1556-1560.
42. Kantarjian H, Giles F, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542-2551.
43. Kantarjian H, Hochhaus A, et al. Nilotinib Is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance. Blood. (ASH Annual Meeting Abstracts). 2007;110:735.
44. Le Coutre P, Giles FJ, et al. Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance. Blood. (ASH Annual Meeting Abstracts). 2007;110:471.
45. Giles FJ, Larson RA, et al. Nilotinib in patients (pts) with Philadelphia chromosome-positive (Phc) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib. Blood. (ASH Annual Meeting Abstracts). 2007;110:1025.
46. Cang S, Liu D. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol. 2008;1:15.
47. Hochhaus A, Erben P, et al. Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol; 2007;44(1 Suppl 1): S15-S24.
48. www.clinicaltrials.gov. Compare bosutinib to imatinib in subjects with newly diagnosed chronic phase Philadelphia chromosome positive CML. ClinicalTrials.gov Identifier: NCT00574873.
49. www.clinicaltrials.gov. A phase III study of dasatinib vs. imatinib in patients with newly diagnosed chronic phase CML. ClinicalTrials.gov Identifier: NCT00481247.
50. www.clinicaltrials.gov. Study of dasatinib in patients with chronic myelogenous leukemia ClinicalTrials.gov Identifier: NCT00254423.
51. Cortes J, O'Brien S, et al. Efficacy of nilotinib (AMN107) in patients (pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). Blood (ASH Annual Meeting Abstracts). 2007;110:29.
52. Cortes J, O'Brien S, et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Blood (ASH Annual Meeting Abstracts). 2007;110:30.
53. www.clinicaltrials.gov. A study of imatinib versus nilotinib in adult patients with newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukemia in chronic phase (CML_CP) (ENEST) ClinicalTrials.gov Identifier: NCT00471497.
54. www.clinicaltrials.gov. A phase III study of dasatinib vs imatinib in patients with newly diagnosed chronic phase CML. ClinicalTrials.gov Identifier: NCT00481247, C. g. I.
55. www.clinicaltrials.gov. A study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Php) chronic myelogenous leukemia in chronic phase (CML-CP) (ENEST). ClinicalTrials.gov Identifier: NCT00471497.